T-cell immunotherapy successfully applied to advanced breast cancer
- Jun 09, 2018 -

Science and Technology Daily, Beijing, June 4th (Reporter Zhang Mengran) British "Nature & Medicine" magazine published an on-line study of cancer science on the 4th: The use of their own T cells, the United States a patient's immune system after adjustment, completely completely removed Breast cancer cells. This is the first time that T-cell immunotherapy has been successfully applied to advanced breast cancer, which also provides a possible treatment for all conventionally ineffective advanced cancers.

    The most successful clinical immunotherapy methods for treating cancer are immune checkpoint blocking and adoptive T cell therapy. The immune checkpoint is blocked by injecting antibodies that activate T cells in the patient; in adoptive T cell therapy, T cells are taken from the patient's blood or tumors, and only T cells that recognize the tumor are cultured and afterwards Return to the patient. At this stage, the success rate of these methods will vary greatly depending on the type of cancer. To date, clinical trials using immunological checkpoint blocking methods to treat breast cancer have proven to be ineffective.

    This time, the National Institutes of Health scientist Steven Rosenberger and his colleagues studied a patient with metastatic breast cancer. When breast cancer cells lose the characteristics of normal cells, free cancer cells can spread throughout the body with blood or lymph to form metastases. Prior to this, the patient had adopted a variety of treatment options and still did not stop the progression of the disease. The team isolated and reactivated their tumor-specific T cells. They found that these reactivated T cells eliminated all metastatic lesions in the patient and she has now been free of disease for two years.

    The research team described the molecular characteristics of these target cancer cells in detail in the paper, and predicted that this method is more likely to be successful in other breast cancer patients. However, they also stressed that this method is still to be confirmed by larger-scale controlled clinical trials.